Jacob Rauchwerger, MD
Pain Medicine · Brooklyn, NYNPI 1295875672
Payments from drug & device makers
Across 521 payments — averaging $79.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Si-bone, Inc.$30K
- Medtronic$3K
- Boston Scientific$2K
- Vertiflex, Inc.$2K
- Relievant Medsystems, Inc.$1K
- Nevro Corp.$964
- plus $3K from 28 others
What the payments were for
- Consulting fees$26,77565%
- Travel & lodging$5,37113%
- Food & beverage$9,25922%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Si-bone, Inc. | 38 | $29,693 |
| Medtronic(2 entities) | 52 | $3,264 |
| Boston Scientific | 175 | $1,941 |
| Vertiflex, Inc. | 10 | $1,922 |
| Relievant Medsystems, Inc. | 24 | $1,001 |
| Nevro Corp. | 64 | $964 |
| Scilex Pharmaceuticals Inc. | 41 | $444 |
| Collegium Pharmaceutical, Inc. | 24 | $331 |
| Tersera Therapeutics LLC | 16 | $306 |
| Arbor Pharmaceuticals, Inc. | 20 | $211 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $208 |
| Biotronik NRO, Inc. | 1 | $137 |
| Painteq LLC | 2 | $127 |
| Spinal Simplicity, LLC | 2 | $126 |
| Spineology Inc. | 1 | $98 |
| Redhill Biopharma Inc. | 6 | $94 |
| Medline Industries LP | 1 | $69 |
| Virtus Pharmaceuticals LLC | 3 | $56 |
| Forte Bio-pharma LLC | 2 | $52 |
| Globus Medical | 2 | $48 |
| Biodelivery Sciences International, Inc. | 3 | $43 |
| Valinor Pharma, LLC | 2 | $42 |
| Shionogi Inc | 2 | $38 |
| Vertex | 1 | $31 |
| Johnson & Johnson | 2 | $30 |
| Nalu Medical, Inc. | 1 | $25 |
| Chiesi USA, Inc. | 1 | $24 |
| Sentynl Therapeutics, Inc. | 2 | $24 |
| Almatica Pharma LLC | 1 | $16 |
| SPR Therapeutics, Inc | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Indivior Inc. | 1 | $12 |
| Acelrx Pharmaceuticals, Inc. | 1 | $12 |
| GRT US Holding, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iFuse Implant$28,352
- Superion ISS$1,826
- Intracept$779
- KYPHON Balloon Kyphoplasty$772
- OSTEOCOOL RF ABLATION SYSTEM$765
- SYNCHROMED$535
- Omnia$314
- GENERAL PAIN MANAGEMENT$162
- Senza Spinal Cord Stimulation System$146
- Prospera$137
- INTELLIS$117
- HA MINUTEMAN G3-R$110
How this compares
$41,429 in reported general payments places this provider in the 95th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 33 | $17,760 |
| Xtampza ErOxycodone Myristate | 13 | $15,497 |
| MovantikNaloxegol Oxalate | 14 | $5,687 |
| Oxycodone Hcl | 186 | $4,712 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 183 | $4,332 |
| Fentanyl | 14 | $2,381 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 65 | $2,228 |
| Pregabalin | 50 | $1,849 |
| Morphine Sulfate ErMorphine Sulfate | 37 | $1,432 |
| Methocarbamol | 58 | $805 |
| Gabapentin | 72 | $602 |
| Amitriptyline Hcl | 91 | $586 |
| Tizanidine Hcl | 42 | $310 |
| Cyclobenzaprine Hcl | 27 | $265 |
| Tramadol Hcl | 16 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $331 | $15,49713 claims |
| Redhill Biopharma Inc.Movantik | $94 | $5,68714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 pain medicine providers in New York.
Other pain medicine in Brooklyn
- Gary SchwartzBrooklyn$756K
- David RosenblumBrooklyn$105K
- Thomas del GuercioBrooklyn$22K
- Jason KreinerBrooklyn$18K
- Roman ShulkinBrooklyn$15K
- Amitabh GulatiNew York$627K
- William CaldwellStony Brook$550K
- Brian DurkinPort Jefferson$459K
- Grace FordeNew Hyde Park$398K
- David SpinnerNew York$391K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.